Takeda appointments former GSK exec as head if CNS research

Takeda Pharmaceutical (TYO: 4502), Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its CNS Drug Discovery Unit, Pharmaceutical Research Division.

Most recently, Emiliangelo Ratti has successfully founded NeRRe Therapeutics Ltd, a biotech spin-out company from UK pharma giant GlaxoSmithKline (LSE: GSK) that is dedicated to the clinical development of a portfolio of neurokinin antagonists, a field in which he is a recognized world-expert. He leads this new start-up as chief executive.

Previously he was senior vice president, head of the GSK Neurosciences Centre of Excellence for Drug Discovery (CEDD), and a member of GSK’s R&D scientific advisory board. Prior to this position he was drug discovery director for one of the three GlaxoWellcome drug discovery groups based in Italy and Spain.